FDA ac­cepts one, de­lays an­oth­er; Da­ta, deals and dol­lars for slate of biotechs

The schiz­o­phre­nia and ma­jor de­pres­sive dis­or­der drug out of Ot­su­ka Phar­ma­ceu­ti­cal and Lund­beck is now un­der pri­or­i­ty re­view at the FDA for an­oth­er in­di­ca­tion. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER